As part of our video series for this year’s DDF 2017 event, life science leaders spoke to us about CRO needs and new regulations.

U.K.-based trial services company Ergomed has penned a deal to buy PSR Group BV, a specialist orphan drug CRO, as it adds to its offerings.

Treos Bio has tapped PPD to manage its first-in-human study on its lead cancer vaccine for colorectal cancer.

A recent study by the Tufts Center for the Study of Drug Development found that EDC systems still aren't efficiently accelerating clinical trials.

Concept Life Sciences has taken two new lab spaces at Alderley Park, adding 55 scientists to sustain its 30% year-over-year growth momentum.

Looking to boost its drug offerings, U.K. CRO Clinigen has paid £150.3 million (around $200 million) to buy out Quantum Pharma.

Parexel has joined forces with the Osaka International Cancer Institute to help “drive greater efficiencies” across trials in Japan.

Arcus inked an $816 million deal for a PD-1 drug developed by Chinese firms WuXi Biologics and Gloria Pharmaceuticals.